Treatment of Helicobacter pylori and Chlamydia pneumoniae infections decreases fibrinogen plasma level in patients with ischemic heart disease

Circulation

Volumn 99, Issue 12, 1999, Pages 1555-1559

  Torgano, Giuseppe ^a   Cosentini, Roberto ^a   Mandelli, Clara ^a   Perondi, Rodolfo ^a   Blasi, Francesco ^a   Bertinieri, Giovanni ^b   Tien, Tu Van ^a   Ceriani, Giuliana ^a   Tarsia, Paolo ^a   Arosio, Cristina ^a   Ranzi, Maria Luisa ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b Ospedale Maggiore IRCCS ^*

Author keywords

C pneumoniae; Fibrinogen; H pylori; Ischemia

Indexed keywords

CLARITHROMYCIN; FIBRINOGEN; OMEPRAZOLE; TINIDAZOLE;

AGE; ANTIBIOTIC THERAPY; ANTIBODY TITER; ARTICLE; CARDIOVASCULAR RISK; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FIBRINOGEN BLOOD LEVEL; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

EID: 0033616863     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.12.1555     Document Type: Article

References (39)

1. Nieminen MS, Mattila K, Valtonen V. Infection and inflammation as a risk factor for myocardial infarction. Eur Heart J. 1993;14(suppl K): 12-16.
2. Alexander RW. Inflammation and coronary artery disease. N Engl J Med. 1994;331:468-469.
3. Beneditt EP, Barret T, McDougall JK. Viruses and etiology of atherosclerosis. Proc Natl Acad Sci U S A. 1983;80:6386-6389.
4. Pesonen E, Siitonen O. Acute myocardial infarction precipitated by infectious diseases. Am Heart J. 1981;101:512-513.
5. Spodick DH, Flessas AP, Johnson MM. Association of acute respiratory symptoms with onset of acute myocardial infarction: prospective investigation of 150 consecutive patients and matched control patients. Am J Cardiol. 1984;53:481-482.
6. Saikku P. Chlamydia pneumoniae as a risk factor in acute myocardial infarction. Eur Heart J. 1993;14(suppl K):62-65.
7. Saikku P, Leinonen M, Mattila K, Ekman MR, Nieminen MS, Makela PH, Huttunen JK, Valtonen V. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet. 1988;2:983-986.
8. Shor A, Kuo CC, Patton DL. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S Afr Med J. 1992;82:158-161.
9. Kuo CC, Shor A, Campbell LA, Fukushi H, Patton DL, Grayston JT. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis. 1993;167:845-849.
10. Mendall MA, Goggin PM, Molineaux N, Levy J, Toosy T, Stracham D, Camm AJ, Northfield TC. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J. 1994;71:437-439.
11. Aceti A, Mazzacurati G, Amendola MA, Pennica A, Zecchini B. H pylori and C pneumoniae infections may account for most acute coronary syndrome. BMJ. 1996;313:428-429.
12. Morgando A, Sanseverino P, Perotto C, Molino F, Gai V, Ponzetto A. Helicobacter pylori seropositivity in myocardial infarction. Lancet. 1995; 345:1380. Letter.
13. Patel P, Carrington D, Strachan DP, Leatham E, Goggin P, Nothfield T, Mendall MA, Fibrinogen: a link between chronic infection and coronary heart disease. Lancet. 1994;343:1634-1635.
14. Wald NJ, Law MR, Morris JK, Bagnall AM. Helicobacter pylon infection and mortality from ischaemic heart disease: negative result from a large, prospective study. BMJ. 1997;315:1199-1201.
15. Jones DM, Lessels AM, Eldridge J. Campylobacter-like organisms on the gastric mucosae: culture, histological and serological studies. J Clin Pathol. 1994;37:1002-1006.
16. Wang SP, Grayston JT. Serological relationship between genital TRIC, lymphogranuloma venereum, and related organisms in a new microtiter indirect immunofluorescence test. Am J Ophthalmol. 1970;70:367-374.
17. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 1997;96:404-407.
18. Clauss A. Gerinnungsphysiologische Scellmethode zur Bstimmung des Fibrinogens. Acta Haematol. 1957;17:237-246.
19. Pocock SJ. Clinical Trials: A Practical Approach. New York, NY: John Wiley & Sons; 1983:123-130.
20. Bazzoli F, Zagari RM, Fossi S, Pozzato P, Alampi G, Simoni P, Sottili S, Roda A, Roda E. Short term, low dose triple therapy for eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol. 1994;6:773-777.
21. Hammerschlag MR, Qumei KK, Roblin PM. In vitro activity of azitromycin, claritromycin, L-ofloxacin and other antibiotics against Chlamvdia pneumoniae. Antimicrob Agents Chemother. 1992;36: 1573-1574.
22. Blasi F, Cosentini R, Tarsia P, Camusso L, Campi E, Arosio C, Allegra L. Chlamydia pneumoniae pneumonia: role of new macrolides. J Chemother. 1995;7:117-118.
23. Armitage P. Statistical Methods in Medical Research. Oxford, UK: Blackwell Scientific Publications; 1971:336.
24. Daniel C, Wood FS. Fitting Equations to Data. New York, NY: Wiley Imerscience; 1971:50-59, 83-115.
25. Burton DE. Query: completed runs of length k above and below median. Technometrics. 1967;9:682-694.
26. Wilk MB, Shapiro SS. The joint assessment of normality for several independent samples. Technometrics. 1968;10:825-839.
27. Blasi F, Denti F, Erba M, Cosentini R, Raccanelli R, Rinaldi A, Fagetti L, Esposito E, Ruberti U, Allegra L. Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms. J Clin Microbiol. 1996;34:2766-2769.
28. Gupta S, Camm JA. Chlamydia pneumoniae and coronary heart disease. BMJ. 1997;314:1778-1779.
29. Ernst E. Fibrinogen as a cardiovascular risk factor: interrelationship with infections and inflammation. Eur Heart J. 1993;14(suppl K):82-87.
30. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: meta-analysis and review of the literature. Ann Intern Med. 1993:118:956-963.
31. Murray LJ, Bamford K, O'Reilly DPJ, McCrum EE, Evans AE. Helicobacter pylori infection: relation with cardiovascular risk factors, ischaemic heart disease, and social class. Br Heart J. 1995;74:497-501.
32. Rathbone B, Martin D, Stephens J, Thompson JR, Samani NJ. Helicobacter pylori seropositivity in subjects with acute myocardial infarction. Heart. 1996;76:308-311.
33. Parente F, Maconi G, Imbesi V, Sangaletti O, Poggio M, Rossi E, Duca P, Bianchi Porro G. Helicobacter pylori infection and coagulation in healthy people. BMJ. 1997;314:1318-1319.
34. Sung JJY, Sanderson JE. Hyperhomocysteinaemia, Helicobacter pylori, and coronary heart disease. Heart. 1996;76:305-307.
35. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B, for the ROXIS Study Group. Randomised trial of roxithomycin in non Q-wave coronary syndromes: ROXIS pilot study. Lancet. 1997;350:404-407.
36. Agen C, Danesi R, Blandizzi C, Costa M, Stacchini B, Favini P, Del Tacca M. Macrolide antibiotics as antiinflammatory agents: roxithromycin in an unexpected role. Agents Actions. 1993;38:1-2, 85-90.
37. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med. 1994;331: 417-424.
38. Leinonen M. Pathogenetic mechanisms and epidemiology of Chlamydia pneuinoniae. Eur Heart J. 1993;14(Suppl K):57-61.
39. Mégraud F. Epidemiology of Helicobacter pylori infection: where are we in 1995? Eur J Gastroenterol Hepatol. 1995;7:292-295.